Laurence A.
- Country
- France
- Department
- Oncology
Research Overview
- Long-term Efficacy and Safety of Belzutifan and Lenvatinib in Patients with von Hippel-Lindau Disease-Associated Tumors and Other Advanced Solid Tumors
- Phase 3 Randomized Study of Belzutifan Plus Zanzalintinib Versus Belzutifan Plus Placebo in Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy
- Phase 1/2a Study of REGN10597 Alone or with Cemiplimab in Patients with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal Cell Carcinoma
Data & Insights
Has run more than one trial at 168 of 339 partner sites.
Specializations
Advanced Renal Cancer Treatment
This investigator specializes in treating advanced renal cell carcinoma, with particular focus on both clear cell and non-clear cell variants of the disease.
- Metastatic RCC Management
- Locally Advanced Disease
- Papillary Renal Cell Carcinoma
The research encompasses various stages of kidney cancer progression and different histological subtypes.
Immunotherapy Applications
Expertise in immune checkpoint inhibitor therapies and their combinations for renal cancer treatment, including novel approaches with targeted therapies.
- Checkpoint Inhibitor Combinations
- Immunotherapy Response Assessment
- Novel Immunotherapy Protocols
Studies focus on optimizing immunotherapy outcomes in various patient populations.
Treatment Innovation
Leading research in combination therapy approaches, including the integration of targeted molecular agents with immunotherapy.
- First-line Treatment Strategies
- Adjuvant Therapy Development
- Treatment Sequencing Studies
Investigation of novel therapeutic combinations and treatment optimization strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.